Currently viewing the tag: "Regulatory Affairs"

The Taiwanese Minister of Health will consider legislation preventing civil servants from accepting key positions in the private sector. It may have its benefits however retired civil servants may be the only agents of change able to interpret public policy for their new employers leading to better alignment between public and private interests. This is not always the case and in many countries regulatory capture is a standard feature of the relationship between government agencies and regulated industries. The two depend on each other and in Taiwan a three year waiting period is unlikely to have a meaningful impact.
Best regards, Joao

*****************

The Department of Health (DOH) will not oppose amending the law to prevent its senior staff from taking jobs at pharmaceutical plants or medical institutions within a specified period after retirement, an official said Friday. DOH Minister Yaung Chih-liang made the remarks in response to an appeal by the Consumers’ Foundation earlier in the day that a “revolving door” clause be introduced to block senior DOH officials from taking positions at health care-related institutions within three years following their retirement from public services. Speaking at a news conference, Consumers’ Foundation Chairman Hsieh Tien-jen said a lot of DOH officials have taken up important positions at medical institutions or pharmaceutical companies shortly after stepping down from department posts.

Source: Focus Taiwan

Tagged with:
 

CAPE TOWN — Precious Matsoso, who headed the Medicines Control Council (MCC) for six years under former health minister Manto Tshabalala-Msimang , has emerged as the frontrunner for the post of health director-general.

The appointment of a new director-general is critical for Health Minister Aaron Motsoaledi’s efforts to improve health services and introduce national health insurance, as he has been without a trusted official in this role since he took office in May last year. Former director-general Thami Mseleku, whom Motsoaledi inherited from the previous administration and was close to Tshabalala-Msimang, resigned in September.

The job is a tough one, as the director-general has to manage a staff of more than 1300, oversee a large budget that includes transfers of billions of rands to the provinces, and guide policy and legislative reform.

Three independent sources told Business Day Matsoso was the preferred candidate among the three people who were recently interviewed for the job. The other two are Nono Simelela, CEO of the South African National Aids Council, and Humphrey Zokufa, chairman of the Board of Healthcare Funders.

The Department of Health is discussing its choice of candidate with the Department of Public Service and Administration, and will then submit its choice to the Cabinet for approval.

The Democratic Alliance (DA) expressed disappointment in the department’s choice. Matsoso was tainted by her association with Tshabalala-Msimang and “took an organisation (the MCC) envied by the world and made it a laughing stock,” said the DA’s health spokesman, Mike Waters. “We don’t think it bodes well. We need a fresh new beginning,” he said.

The MCC was embroiled in controversies over treatment for HIV during the previous administration, including a row over the safety and efficacy of nevirapine. It was also criticised for not doing enough to crack down on quack remedies. However, AIDS Law Project researcher Nathan Geffen disagreed with the DA, saying Matsoso had done a good job of restructuring the MCC.

Matsoso joined the MCC in 1998, and resigned in December 2004 to take up a post as director of the World Health Organisation’s department of technical co- operation for essential drugs and traditional medicine. She then moved on to the post of director for public health innovation and intellectual property.

Source: Tamar Kahn (Business Day)

Tagged with:
 

The European Medicines Agency has today published a draft paper setting out its vision for the strategic development of the Agency over the next five years.

Building on the progress of its previous five-year strategy, the new Road Map to 2015 charts the way forward for the Agency amid rapid developments in medical science and pharmaceutical research, as well as the continuing evolution of the European and international regulatory environments.

With this strategy paper to guide it, the Agency will seek to consolidate its achievements to date and further strengthen its role as a guardian of human and animal health in the European

Road Map to 2015

Source

Tagged with:
 

Facebook

YouTube

LinkedId